A Randomized, Double-blind, Placebo-controlled Phase 3 Study to evaluate Dostarlimab as Sequential Therapy after Chemoradiation in Participants with Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma

  • Haydon, Andrew (Primary Chief Investigator (PCI))

Project: Research

Project Details

StatusActive
Effective start/end date6/03/24 → 6/03/26

Keywords

  • clinical trial
  • Squamous Cell Carcinoma
  • Dostarlimab